UBS Group Issues Positive Forecast for Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price

Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) had its price target upped by UBS Group from $23.00 to $26.00 in a research note released on Wednesday,Benzinga reports. UBS Group currently has a buy rating on the stock. A number of other analysts have also recently issued reports on the company. Wall Street Zen upgraded Teva […]

Leave a Reply

Your email address will not be published.

Previous post JMP Securities Reiterates Market Outperform Rating for Benitec Biopharma (NASDAQ:BNTC)
Next post Citizens Jmp Initiates Coverage on Assembly Biosciences (NASDAQ:ASMB)